No Data
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $115
Korro Bio's Promising Regulatory and Preclinical Advances Earn a Buy Rating From Analyst Mitchell Kapoor
Korro Bio Has Submitted Regulatory Filing To Start Phase 1/2 Study Of KRRO-110 For Alpha-1 Antitrypsin Deficiency, First Participant Dosing Is Anticipated In Q1 Of 2025, With Interim Readout Is Expected In 2H Of 2025, And Completion Of Phase 1/2 Study...
Express News | Korro Bio - Interim Readout Expected in H2 2025 & Completion of Phase 1/2 Study Anticipated in 2026
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
Express News | Korro Announces Regulatory Filing for Initiation of Krro-110 First-in-Human Study and Formation of Clinical Advisory Board
No Data
No Data